Oncology Institute, Inc. (NASDAQ:STLN – Get Free Report) major shareholder Jorey Chernett purchased 48,294 shares of Oncology Institute stock in a transaction that occurred on Monday, November 9th. The shares were bought at an average price of $3.65 per share, with a total value of $176,273.10. Following the transaction, the insider owned 7,858,091 shares in the company, valued at approximately $28,682,032.15. The trade was a 0.62% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Jorey Chernett also recently made the following trade(s):
- On Friday, November 6th, Jorey Chernett sold 2,851,061 shares of Oncology Institute stock. The stock was sold at an average price of $3.99, for a total value of $11,375,733.39.
- On Friday, August 14th, Jorey Chernett bought 12,000 shares of Oncology Institute stock. The shares were acquired at an average cost of $6.54 per share, with a total value of $78,480.00.
Oncology Institute Price Performance
STLN stock opened at $4.20 on Thursday. Oncology Institute, Inc. has a 12 month low of $2.32 and a 12 month high of $7.13. The company has a 50-day simple moving average of $6.32.
Analyst Ratings Changes
STLN has been the topic of several research reports. Needham & Company LLC increased their price target on shares of Oncology Institute from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Lake Street Capital dropped their price objective on shares of Oncology Institute from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a report on Tuesday, November 3rd. B. Riley Financial reaffirmed a “buy” rating and set a $10.00 target price (down from $11.00) on shares of Oncology Institute in a research note on Friday, November 6th. Finally, BTIG Research increased their target price on shares of Oncology Institute from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Oncology Institute currently has a consensus rating of “Moderate Buy” and an average target price of $9.25.
View Our Latest Research Report on STLN
Institutional Investors Weigh In On Oncology Institute
Several institutional investors have recently added to or reduced their stakes in STLN. State Street Corp acquired a new stake in Oncology Institute during the second quarter worth approximately $8,432,000. The Manufacturers Life Insurance Company acquired a new position in shares of Oncology Institute in the 2nd quarter valued at $111,000. WINTON GROUP Ltd acquired a new position in shares of Oncology Institute in the 2nd quarter valued at $102,000. Engineers Gate Manager LP purchased a new position in shares of Oncology Institute in the 2nd quarter valued at $67,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Oncology Institute in the 2nd quarter valued at $396,000. Hedge funds and other institutional investors own 36.86% of the company’s stock.
Oncology Institute Company Profile
The Oncology Institute is a physician-led provider of cancer care. Its services include medical oncology and hematology consultations, cancer treatment and infusion services, pharmacy support, and access to clinical trials. The company combines community-based clinics with care coordination and value-based care programs intended to support patients throughout treatment. It serves patients in several U.S. states, including California, Nevada, Arizona, and Florida. Founded in 2007, The Oncology Institute has expanded its network of oncology clinics and related services to provide cancer care closer to where patients live.
Featured Articles
- Five stocks we like better than Oncology Institute
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.
